• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

139
23
13
13
12

COUNTRY

12
7
4
3
2

PRICE

554
597
648
883

PUBLISHED

2
9
108
883

PRODUCT TYPE

486
396
1

Immune Disorders

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less
Read more

PRODUCT TITLE

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - France Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Rituxan (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Italy Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Italy Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - US Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - UK Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

Atacicept (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Atacicept (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Japan Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

Epratuzumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Epratuzumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that...

October 2013
FROM

Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Blisibimod (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

Benlysta (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Benlysta (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Spain Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 Summary The lupus therapeutics market is dominated by generics and GlaxoSmithKline’s...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis...

October 2013
FROM

Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

Orencia (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Orencia (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Germany Drug Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease...

October 2013
FROM

Lupuzor (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Lupuzor (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022 Summary Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can...

October 2013
FROM

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2013

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2013', provides an overview of the indication’s...

October 2013
FROM

House Dust Mite Allergy - Pipeline Review, H2 2013

House Dust Mite Allergy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'House Dust Mite Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Chronic Plaque Psoriasis - Pipeline Review, H2 2013

Chronic Plaque Psoriasis - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chronic Plaque Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM
Loading Indicator

Our Clients

Our clients' logos